CADL Candel Therapeutics, Inc.
$8.25▲ +5.91%
Healthcare
Other
After hours
$8.25▲ +0.00%
Oct 27, 4:01 PM ET
Volume 928.4K
Avg Volume (10D) 1.09M
Key Metrics & Fundamentals
Market Cap
$631.28M
P/E Ratio
–
Div Yield
0.00%
52W Range
4.35 - 14.00
% vs 50 MA
-24.49%
% vs 200 MA
0.06%
RSI-14
34.8
MACD Histogram
-0.0500
Beta (1Y vs SPY)
1.90
Free Cash Flow
-$17.25M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$24.88M
COGS
–
Operating Exp
$26.72M
Operating Income
-$26.72M
EBIT
-$26.72M
Pretax Income
-$38.91M
Net Income
-$38.91M
EPS (Diluted)
-0.52
Price & Volume History
Loading chart…
Recent News
Candel Therapeutics to Present at November Investor Conferences
GlobeNewswire · Oct 27, 2026 8:05 AM ET
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
GlobeNewswire · Oct 22, 2026 8:05 AM ET
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
GlobeNewswire · Oct 2, 2026 9:00 AM ET
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 1, 2026 4:05 PM ET
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
GlobeNewswire · Oct 1, 2026 8:05 AM ET
CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
Stocktwits · Sep 30, 2026 11:00 AM ET
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
GlobeNewswire · Sep 30, 2026 8:30 AM ET
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
GlobeNewswire · Sep 30, 2026 8:05 AM ET
Candel Therapeutics Shares Rise After BofA Upgrade
MT Newswires · Sep 21, 2026 2:37 PM ET
BofA Upgrades Candel Therapeutics to Buy From Neutral, Price Target is $18
MT Newswires · Sep 21, 2026 6:53 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CADL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.